MOLECULAR PATHOLOGY WORKING GROUP

Chair: Giorgio Stanta
Secretary: Gerald Hoefler

ACTIVITIES OF THE GROUP IN 2015:
1. ACTIVE WORKING GROUPS:
   - OECI-ESP-IMPACTS European Working Group for the Development of SOPs and IQC for DNA and RNA Extraction, Quantification and Quality Analysis in Molecular Archive Tissue Diagnostics. (G. Stanta)
   - ESP Working Group on Next Generation Sequencing in Diagnostics. (G. Hoefler)
   - ESP Pre-Analytical Tissue Condition Working Groups. (C. Marchiò)
   - ESP – Heterogeneity, inter-WGs of ESP. (G. Stanta)
   - ESP – Proteomics SOPs in AT, in development. (K. Becker)

2. OTHER ACTIVITIES CARRIED OUT IN 2015:
   - 11-13 May: organization and implementation of “EACR-OECI-ESP 5th EACR-OECI Joint Training Course Molecular Pathology approach to Cancer”. The course was held in Amsterdam. This course was an advanced course on Molecular Pathology of Cancer, with some of the most experienced scientists in the field. It was very successful and attracted participants not only from Europe.
   - 22-23 June: OECI, ESP, BBMRI-ERIC, EuroCan Platform, IMPACTS Pathology meeting in Porto, Portugal: “Tumour Heterogeneity and Next Generation Sequencing: Morphology and Technology”. During the meeting tumour heterogeneity was discussed as clonal and non-clonal evolution. Three round tables were also held, related to tumour heterogeneity and industry, heterogeneity and tissue biobanking, heterogeneity and different tumour types, similarities and differences. For this latest round table, a document on how to approach tumour heterogeneity in the different tumour types is in development by the chairs of the different Working Groups of the European Society of Pathology.
   - 13-14 July: “Advances in Diagnostic Molecular Pathology” course, held in Graz. Basic course for pathologists and molecular biologists in practical clinical diagnostics.
   - 5-9 September: ESP Congress, Belgrade. Organization of:
     a. Molecular Pathology Heterogeneity Session: “Does tumor heterogeneity interfere with predictive biomarker evaluation?”
     b. Joint session Molecular Pathology - Haematopathology: “Early genetic lesions in lymphomas”
     c. Joint session Infectious Diseases Pathology - Molecular Pathology: “Microbes and tumours: An update”